Vaccination of patients with autoimmune inflammatory rheumatic diseases

Nature Reviews Rheumatology

Volumn 11, Issue 3, 2015, Pages 135-145

  Westra, Johanna ^a   Rondaan, Christien ^a   Van Assen, Sander ^a   Bijl, Marc ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AZATHIOPRINE; BCG VACCINE; CERTOLIZUMAB PEGOL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INFLUENZA VACCINE; LEFLUNOMIDE; MENINGOCOCCUS VACCINE; METHOTREXATE; MYCOPHENOLIC ACID; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB; STEROID; TETANUS TOXOID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; VACCINE;

AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; APHTHOUS ULCER; AUTOIMMUNE DISEASE; AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASE; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INCIDENCE; INFECTION RISK; INFLUENZA; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; WEGENER GRANULOMATOSIS; ADVERSE EFFECTS; AGED; AUTOIMMUNE DISEASES; IMMUNOLOGY; MALE; MIDDLE AGED; PROCEDURES; RHEUMATIC DISEASES;

AGED; AUTOIMMUNE DISEASES; HUMANS; MALE; MIDDLE AGED; RHEUMATIC DISEASES; VACCINATION; VACCINES;

EID: 84924180678     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.206     Document Type: Review

References (153)

1. Mandell, B. F. Vaccination: an option not to be ignored. Cleve. Clin. J. Med. 77, 151 (2010
2. Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401-409 (2008
3. Touma, Z., Gladman, D. D. & Urowitz, M. B. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr. Opin. Rheumatol. 25, 164-170 (2013
4. Murdaca, G., et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun. Rev. 13, 75-84 (2014
5. Van Assen, S., et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun. Rev. 10, 341-352 (2011
6. Hohensinner, P. J., Goronzy, J. J. & Weyand, C. M. Telomere dysfunction, autoimmunity and aging. Aging Dis. 2, 524-537 (2011
7. Stampfli, M. R. & Anderson, G. P. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 9, 377-384 (2009
8. Listing, J., Gerhold, K. & Zink, A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52, 53-61 (2013
9. Germano, V., et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J. Transl. Med. http://dx.doi.org/10.1186/1479-5876-12-77
10. Sciascia, S., Cuadrado, M. J. & Karim, M. Y. Management of infection in systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. 27, 377-389 (2013
11. Curtis, J. R., et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66, 990-997 (2014
12. Ruiz-Irastorza, G., et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res. Ther. 11, R109 (2009
13. Nichol, K. L., Wuorenma, J. & von Sternberg, T. Benefits of influenza vaccination for low , intermediate , and high-risk senior citizens. Arch. Intern. Med. 158, 1769-1776 (1998
14. Hak, E., et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin. Infect. Dis. 35, 370-377 (2002
15. Blumentals, W. A., Arreglado, A., Napalkov, P. & Toovey, S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet. Disord. 13, 158 (2012
16. Wotton, C. J. & Goldacre, M. J. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J. Epidemiol. Community Health 66, 1177-1181 (2012
17. Yee, A. M., Ng, S. C., Sobel, R. E. & Salmon, J. E. FcγRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis Rheum. 40, 1180-1182 (1997
18. Klippel, J. H., et al. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum. 22, 1321-1325 (1979
19. Naveau, C. & Houssiau, F. A. Pneumococcal sepsis in patients with systemic lupus erythematosus. Lupus 14, 903-906 (2005
20. Lu, T. Y., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61, 482-487 (2009
21. Favalli, E. G., et al. Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun. Rev. 8, 266-273 (2009
22. Strangfeld, A., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF α agents. JAMA 301, 737-744 (2009
23. Antonelli, M. A., Moreland, L. W. & Brick, J. E. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am. J. Med. 90, 295-298 (1991
24. McDonald, J. R., et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin. Infect. Dis. 48, 1364-1371 (2009
25. Smitten, A. L., et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 57, 1431-1438 (2007
26. Speerstra, F., et al. Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience. Ann. Rheum. Dis. 41, (Suppl. 1) 37-39 (1982
27. Wolfe, F., Michaud, K. & Chakravarty, E. F. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 45, 1370-1375 (2006
28. Garcia-Doval, I., et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann. Rheum. Dis. 69, 1751-1755 (2010
29. Winthrop, K. L., et al. Association between the initiation of anti-Tumor necrosis factor therapy and the risk of herpes zoster. JAMA 309, 887-895 (2013
30. Ramiro, S., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann. Rheum. Dis. 73, 529-535 (2014
31. Kahl, L. E. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J. Rheumatol. 21, 84-86 (1994
32. Kang, T. Y., Lee, H. S., Kim, T. H., Jun, J. B. & Yoo, D. H. Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. Rheumatol. Int. 25, 97-102 (2005
33. Manzi, S., et al. Herpes zoster in systemic lupus erythematosus. J. Rheumatol. 22, 1254-1258 (1995
34. Chakravarty, E. F., Michaud, K., Katz, R. & Wolfe, F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus 22, 238-244 (2013
35. Ginzler, E., et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum. 21, 37-44 (1978
36. Nagaoka, S., et al. Herpes zoster in patients with polymyositis and dermatomyositis. Kansenshogaku Zasshi 64, 1394-1399 (1990
37. Nagasawa, K., et al. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann. Rheum. Dis. 49, 630-633 (1990
38. Wang, F., Chua, C. T. & Bosco, J. Herpes zoster in patients with systemic lupus erythematosus. Singapore Med. J. 24, 218-220 (1983
39. Dubois, E. L. & Tuffanelli, D. L. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA 190, 104-111 (1964
40. Ishikawa, O., Abe, M. & Miyachi, Y. Herpes zoster in Japanese patients with systemic lupus erythematosus. Clin. Exp. Dermatol. 24, 327-328 (1999
41. Janwityanuchit, S., Totemchokchyakarn, K., Krachangwongchai, K. & Vatanasuk, M. Infection in systemic lupus erythematosus. J. Med. Assoc. Thai. 76, 542-548 (1993
42. Moutsopoulos, H. M., Gallagher, J. D., Decker, J. L. & Steinberg, A. D. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum. 21, 798-802 (1978
43. Borba, E. F., et al. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus. J. Clin. Rheumatol. 16, 119-122 (2010
44. Della-Torre, E., et al. Individualized therapy provides better outcome in patients with proliferative lupus nephritis: follow up of a cohort of Italian patients [abstract]. Ann. Rheum. Dis. 68 (Suppl. 3), 247 (2009
45. Tokunaga, M., et al. Efficacy of rituximab (anti CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66, 470-475 (2007
46. Mak, A., et al. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-Analysis and meta-regression. Rheumatology (Oxford) 48, 944-952 (2009
47. Merrill, J. T., et al. Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222-233 (2010
48. Wung, P. K., et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am. J. Med. 118, 1416 (2005
49. Tam, L. S., Chan, A. Y., Chan, P. K., Chang, A. R. & Li, E. K. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 50, 3619-3625 (2004
50. Nath, R., et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 57, 619-625 (2007
51. Lee, Y. H., et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J. Korean Med. Sci. 25, 1431-1437 (2010
52. Tam, L. S., et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus-A prospective cohort study. J. Rheumatol. 37, 330-340 (2010
53. Stojanovich, L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin. Dev. Immunol. 13, 373-375 (2006
54. Kobashigawa, T., et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand. J. Rheumatol. 42, 445-450 (2013
55. Kostianovsky, A., et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin. Exp. Rheumatol. 30 (1 Suppl. 70), S83-S89 (2012
56. De Jong, J. C., et al. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. (Basel) 115, 63-73 (2003
57. Chalmers, A., et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J. Rheumatol. 21, 1203-1206 (1994
58. Del Porto, F., et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 24, 3217-3223 (2006
59. Denman, E. J., Denman, A. M., Greenwood, B. M., Gall, D. & Heath, R. B. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann. Rheum. Dis. 29, 220-231 (1970
60. Fomin, I., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF α blockers. Ann. Rheum. Dis. 65, 191-194 (2006
61. Gelinck, L. B., et al. The effect of anti-Tumour necrosis factor α treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis. 67, 713-716 (2008
62. Herron, A., et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 242, 53-56 (1979
63. Kaine, J. L., Kivitz, A. J., Birbara, C. & Luo, A. Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34, 272-279 (2007
64. Kubota, T., et al. Anti-Tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod. Rheumatol. 17, 531-533 (2007
65. Nii, T., et al. Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. Mod. Rheumatol. 19, 216-218 (2009
66. Turner-Stokes, L., Cambridge, G., Corcoran, T., Oxford, J. S. & Snaith, M. L. In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann. Rheum. Dis. 47, 532-535 (1988
67. Van Assen, S., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 62, 75-81 (2010
68. Elkayam, O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin. Dev. Immunol. 13, 349-351 (2006
69. Kapetanovic, M. C., Saxne, T., Nilsson, J. A. & Geborek, P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 46, 608-611 (2007
70. Kivitz, A. J., et al. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J. Rheumatol. 41, 648-657 (2014
71. Elkayam, O., et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis Rheum. 39, 442-447 (2010
72. Gelinck, L. B., et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann. Rheum. Dis. 66, 1402-1403 (2007
73. Kapetanovic, M. C. Further evidence for influenza and pneumococcal vaccination in patients treated with disease modifying antirheumatic drugs and anti-Tumor necrosis factor agents. J. Rheumatol. 41, 626-628 (2014
74. Kapetanovic, M. C., et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res. Ther. 16, R2 (2014
75. Oren, S., et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann. Rheum. Dis. 67, 937-941 (2008
76. Elkayam, O., et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res. (Hoboken) 63, 1062-1067 (2011
77. Mori, S., et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann. Rheum. Dis. 71, 2006-2010 (2012
78. Ribeiro, A. C., et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 65, 476-480 (2013
79. Williams, G. W., et al. Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann. Intern. Med. 88, 729-734 (1978
80. Holvast, A., et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann. Rheum. Dis. 65, 913-918 (2006
81. Mercado, U., Acosta, H. & Avendano, L. Influenza vaccination of patients with systemic lupus erythematosus. Rev. Invest. Clin. 56, 16-20 (2004
82. Wiesik-Szewczyk, E., et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin. Rheumatol. 29, 605-613 (2010
83. Brodman, R., Gilfillan, R., Glass, D. & Schur, P. H. Influenzal vaccine response in systemic lupus erythematosus. Ann. Intern. Med. 88, 735-740 (1978
84. Louie, J. S., et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann. Intern. Med. 88, 790-792 (1978
85. Pons, V. G., Reinertsen, J. L., Steinberg, A. D. & Dolin, R. Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J. Med. Virol. 4, 15-23 (1979
86. Ristow, S. C., Douglas, R. G. Jr & Condemi, J. J. Influenza vaccination of patients with systemic lupus erythematosus. Ann. Intern. Med. 88, 786-789 (1978
87. Abu-Shakra, M., et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J. Rheumatol. 29, 2555-2557 (2002
88. Crowe, S. R., et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum. 63, 2396-2406 (2011
89. Holvast, A., et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford) 48, 1294-1299 (2009
90. Holvast, A., et al. Wegeners granulomatosis patients show an adequate antibody response to influenza vaccination. Ann. Rheum. Dis. 68, 873-878 (2009
91. Zycinska, K., et al. Antibody response to inactivated subunit influenza vaccine in patients with Wegeners granulomatosis. J. Physiol. Pharmacol. 58 (Suppl. 5), 819-828 (2007
92. Setti, M., et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 27, 3367-3372 (2009
93. Saad, C. G., et al. Immunogenicity and safety of the 2009 non-Adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann. Rheum. Dis. 70, 1068-1073 (2011
94. Gabay, C., et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-Adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 63, 1486-1496 (2011
95. Iwamoto, M., et al. Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol. Int. 32, 3691-3694 (2012
96. Mathian, A., et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum. 63, 3502-3511 (2011
97. Lu, C. C., et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 29, 444-450 (2011
98. Pasoto, S. G., et al. Short and long-Term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögrens syndrome. Vaccine 31, 1793-1798 (2013
99. Arad, U., et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 29, 1643-1648 (2011
100. Holvast, A., et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum. 60, 2438-2447 (2009
101. Coulson, E., et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann. Rheum. Dis. 70, 1289-1291 (2011
102. Visvanathan, S., Keenan, G. F., Baker, D. G., Levinson, A. I. & Wagner, C. L. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J. Rheumatol. 34, 952-957 (2007)
103. Kapetanovic, M. C., et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45, 106-111 (2006
104. Bingham, C. O. 3rd, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 62, 64-74 (2010
105. Elkayam, O., et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin. Infect. Dis. 34, 147-153 (2002
106. Elkayam, O., Caspi, D., Reitblatt, T., Charboneau, D. & Rubins, J. B. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis Rheum. 33, 283-288 (2004
107. Kapetanovic, M. C., et al. Antibody response is reduced following vaccination with 7 valent conjugate pneumococcal vaccine in adult methotrexate-Treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 63, 3723-3732 (2011
108. Kapetanovic, M. C., Roseman, C., Jönsson, G. & Truedsson, L. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23 valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs. Clin. Rheumatol. 30, 1555-1561 (2011
109. Mori, S., et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann. Rheum. Dis. 72, 1362-1366 (2013
110. Bingham, C. O. 3rd, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-204427
111. Croft, S. M., et al. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus. J. Rheumatol. 11, 141-146 (1984
112. Lipnick, R. N., et al. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J. Rheumatol. 12, 1118-1121 (1985
113. Battafarano, D. F., et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 41, 1828-1834 (1998
114. Jarrett, M. P., Schiffman, G., Barland, P. & Grayzel, A. I. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. Arthritis Rheum. 23, 1287-1293 (1980
115. McDonald, E., Jarrett, M. P., Schiffman, G. & Grayzel, A. I. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J. Rheumatol. 11, 306-308 (1984
116. Tarjan, P., et al. No short-Term immunological effects of Pneumococcus vaccination in patients with systemic lupus erythematosus. Scand. J. Rheumatol. 31, 211-215 (2002
117. Franco Salinas, G., et al. TNF blockade impairs T cell dependent antibody responses [abstract]. Ann. Rheum. Dis. 68 (Suppl. 3), 238 (2009
118. Mease, P. J., et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J. Rheumatol. 31, 1356-1361 (2004
119. Mercado, U., Acosta, H. & Diaz-Molina, R. Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis. J. Rheumatol. 36, 1549-1550 (2009
120. Kuruma, K. A., Borba, E. F., Lopes, M. H., de Carvalho, J. F. & Bonfá, E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 16, 350-354 (2007
121. Erkek, E., Ayaslioglu, E., Erkek, A. B., Kurtipek, G. S. & Bagci, Y. Response to vaccination against hepatitis B in patients with Behcets disease. J. Gastroenterol. Hepatol. 20, 1508-1511 (2005
122. Devey, M. E., Bleasdale, K. & Isenberg, D. A. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin. Exp. Immunol. 68, 562-569 (1987
123. Abe, T. & Homma, M. Immunological reactivity in patients with systemic lupus erythematosus. Humoral antibody and cellular immune responses. Acta Rheumatol. Scand. 17, 35-46 (1971
124. Kashef, S., Ghazizadeh, F., Derakhshan, A., Farjadian, S. & Alyasin, S. Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran. J. Immunol. 5, 181-184 (2008
125. Nies, K., Boyer, R., Stevens, R. & Louie, J. Anti-Tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses. Arthritis Rheum. 23, 1343-1350 (1980
126. Askling, H. H., et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med. Infect. Dis. 12, 134-142 (2014
127. Mok, C. C., Ho, L. Y., Fong, L. S. & To, C. H. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann. Rheum. Dis. 72, 659-664 (2013
128. Soybilgic, A., Onel, K. B., Utset, T., Alexander, K. & Wagner-Weiner, L. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr. Rheumatol. Online J. 11, 29 (2013
129. Van Assen, S., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 70, 414-422 (2011
130. Singh, J. A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care. Res. (Hoboken) 64, 625-639 (2012
131. Zhang, J., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 308, 43-49 (2012
132. Guthridge, J. M., et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J. Rheumatol. 40, 1875-1880 (2013
133. Shoenfeld, Y. & Agmon-Levin, N. ASIA-Autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 36, 4-8 (2011
134. Colafrancesco, S., Perricone, C., Priori, R., Valesini, G. & Shoenfeld, Y. Sjögrens syndrome: another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). J. Autoimmun. 51, 10-16 (2014
135. Perricone, C., et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J. Autoimmun. 47, 1-16 (2013
136. Borchers, A. T., Keen, C. L., Shoenfeld, Y., Silva, J. Jr & Gershwin, M. E. Vaccines, viruses, and voodoo. J. Investig. Allergol. Clin. Immunol. 12, 155-168 (2002
137. Bengtsson, C., et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann. Rheum. Dis. 69, 1831-1833 (2010
138. Grimaldi-Bensouda, L., et al. The risk of systemic lupus erythematosus associated with vaccines: an international case-control study. Arthritis Rheumatol. 66, 1559-1567 (2014
139. Perdan-Pirkmajer, K., et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus 21, 175-183 (2012
140. Lu, C. C., et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 29, 444-450 (2011
141. Urowitz, M. B., Anton, A., Ibanez, D. & Gladman, D. D. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 63, 1517-1520 (2011
142. Milanetti, F., et al. Safety and immunogenicity of co-Administered MF59-Adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin. Exp. Immunol. 177, 287-294 (2014
143. Aikawa, N. E., et al. Effective seroconversion and safety following the pandemic influenza vaccination (anti H1N1) in patients with juvenile idiopathic arthritis. Scand. J. Rheumatol. 42, 34-40 (2013
144. Stassen, P. M., Sanders, J. S., Kallenberg, C. G. & Stegeman, C. A. Influenza vaccination does not result in an increase in relapses in patients with ANCA-Associated vasculitis. Nephrol. Dial. Transplant. 23, 654-658 (2008
145. Karsh, J., Pavlidis, N., Schiffman, G. & Moutsopoulos, H. M. Immunization of patients with Sjögrens syndrome with pneumococcal polysaccharide vaccine: a randomized trial. Arthritis Rheum. 23, 1294-1298 (1980
146. Grimaldi-Bensouda, L., et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J. Intern. Med. 275, 398-408 (2014
147. Gatto, M., et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin. Rheumatol. 32, 1301-1307 (2013
148. Soldevilla, H F., Briones, S. F. & Navarra, S. V. Systemic lupus erythematosus following HPV immunization or infection? Lupus 21, 158-161 (2012
149. Zhang, J., et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res. Ther. 13, R174 (2011
150. Heijstek, M. W., et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann. Rheum. Dis. 70, 1704-1712 (2011).
151. Galloway, J. B., et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-Tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 72, 229-234 (2013
152. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report (MMWR) [online], http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm (2011
153. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report (MMWR) [online], http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm (2011